Jefferies Group LLC assumed coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research note issued on Thursday. The brokerage set a “buy” rating and a $101.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s price objective suggests a potential upside of 51.88% from the stock’s current price.
A number of other research analysts have also weighed in on the company. JMP Securities raised their price objective on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group lifted their target price on AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Wedbush reissued an “outperform” rating and issued a $75.00 target price (up previously from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. Finally, Royal Bank of Canada initiated coverage on AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $76.25.
AnaptysBio (ANAB) traded down $0.60 during mid-day trading on Thursday, reaching $66.50. The company had a trading volume of 199,900 shares, compared to its average volume of 201,494. AnaptysBio has a one year low of $15.17 and a one year high of $74.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 11.50.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. equities research analysts forecast that AnaptysBio will post -1.84 earnings per share for the current fiscal year.
WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/anaptysbio-inc-anab-now-covered-by-jefferies-group-llc.html.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $21.10, for a total value of $7,517,930.00. Following the transaction, the insider now directly owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Several hedge funds have recently added to or reduced their stakes in ANAB. Citadel Advisors LLC purchased a new position in AnaptysBio during the third quarter valued at $20,406,000. Artal Group S.A. lifted its position in AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after purchasing an additional 205,310 shares in the last quarter. JPMorgan Chase & Co. lifted its position in AnaptysBio by 210.2% during the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after purchasing an additional 124,219 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in AnaptysBio during the third quarter valued at $2,796,000. Finally, State of New Jersey Common Pension Fund D purchased a new position in AnaptysBio during the third quarter valued at $1,922,000. Hedge funds and other institutional investors own 59.40% of the company’s stock.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.